Report cover image

Global Varicella Vaccine Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 199 Pages
SKU # APRC20284179

Description

Summary

According to APO Research, The global Varicella Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Varicella Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Varicella Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Varicella Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Varicella Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Varicella Vaccine include BCHT, Biken, Changsheng, Green Cross, Keygen, GSK, Merck and Shanghai Institute, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Varicella Vaccine, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Varicella Vaccine, also provides the revenue of main regions and countries. Of the upcoming market potential for Varicella Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Varicella Vaccine revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Varicella Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Varicella Vaccine revenue, projected growth trends, production technology, application and end-user industry.

Varicella Vaccine Segment by Company

BCHT
Biken
Changsheng
Green Cross
Keygen
GSK
Merck
Shanghai Institute
Varicella Vaccine Segment by Type

Injection
Freeze-Dried Powder
Varicella Vaccine Segment by Application

Kids Injection
Adults Injection
Varicella Vaccine Segment by Region

North America
United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Varicella Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Varicella Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Varicella Vaccine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Varicella Vaccine revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Varicella Vaccine Market by Type
1.2.1 Global Varicella Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Injection
1.2.3 Freeze-Dried Powder
1.3 Varicella Vaccine Market by Application
1.3.1 Global Varicella Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Kids Injection
1.3.3 Adults Injection
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Varicella Vaccine Market Dynamics
2.1 Varicella Vaccine Industry Trends
2.2 Varicella Vaccine Industry Drivers
2.3 Varicella Vaccine Industry Opportunities and Challenges
2.4 Varicella Vaccine Industry Restraints
3 Global Growth Perspective
3.1 Global Varicella Vaccine Market Perspective (2020-2031)
3.2 Global Varicella Vaccine Growth Trends by Region
3.2.1 Global Varicella Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Varicella Vaccine Market Size by Region (2020-2025)
3.2.3 Global Varicella Vaccine Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Varicella Vaccine Revenue by Players
4.1.1 Global Varicella Vaccine Revenue by Players (2020-2025)
4.1.2 Global Varicella Vaccine Revenue Market Share by Players (2020-2025)
4.1.3 Global Varicella Vaccine Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Varicella Vaccine Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Varicella Vaccine Key Players Headquarters & Area Served
4.4 Global Varicella Vaccine Players, Product Type & Application
4.5 Global Varicella Vaccine Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Varicella Vaccine Market CR5 and HHI
4.6.3 2024 Varicella Vaccine Tier 1, Tier 2, and Tier 3
5 Varicella Vaccine Market Size by Type
5.1 Global Varicella Vaccine Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Varicella Vaccine Revenue by Type (2020-2031)
5.3 Global Varicella Vaccine Revenue Market Share by Type (2020-2031)
6 Varicella Vaccine Market Size by Application
6.1 Global Varicella Vaccine Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Varicella Vaccine Revenue by Application (2020-2031)
6.3 Global Varicella Vaccine Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 BCHT
7.1.1 BCHT Comapny Information
7.1.2 BCHT Business Overview
7.1.3 BCHT Varicella Vaccine Revenue and Gross Margin (2020-2025)
7.1.4 BCHT Varicella Vaccine Product Portfolio
7.1.5 BCHT Recent Developments
7.2 Biken
7.2.1 Biken Comapny Information
7.2.2 Biken Business Overview
7.2.3 Biken Varicella Vaccine Revenue and Gross Margin (2020-2025)
7.2.4 Biken Varicella Vaccine Product Portfolio
7.2.5 Biken Recent Developments
7.3 Changsheng
7.3.1 Changsheng Comapny Information
7.3.2 Changsheng Business Overview
7.3.3 Changsheng Varicella Vaccine Revenue and Gross Margin (2020-2025)
7.3.4 Changsheng Varicella Vaccine Product Portfolio
7.3.5 Changsheng Recent Developments
7.4 Green Cross
7.4.1 Green Cross Comapny Information
7.4.2 Green Cross Business Overview
7.4.3 Green Cross Varicella Vaccine Revenue and Gross Margin (2020-2025)
7.4.4 Green Cross Varicella Vaccine Product Portfolio
7.4.5 Green Cross Recent Developments
7.5 Keygen
7.5.1 Keygen Comapny Information
7.5.2 Keygen Business Overview
7.5.3 Keygen Varicella Vaccine Revenue and Gross Margin (2020-2025)
7.5.4 Keygen Varicella Vaccine Product Portfolio
7.5.5 Keygen Recent Developments
7.6 GSK
7.6.1 GSK Comapny Information
7.6.2 GSK Business Overview
7.6.3 GSK Varicella Vaccine Revenue and Gross Margin (2020-2025)
7.6.4 GSK Varicella Vaccine Product Portfolio
7.6.5 GSK Recent Developments
7.7 Merck
7.7.1 Merck Comapny Information
7.7.2 Merck Business Overview
7.7.3 Merck Varicella Vaccine Revenue and Gross Margin (2020-2025)
7.7.4 Merck Varicella Vaccine Product Portfolio
7.7.5 Merck Recent Developments
7.8 Shanghai Institute
7.8.1 Shanghai Institute Comapny Information
7.8.2 Shanghai Institute Business Overview
7.8.3 Shanghai Institute Varicella Vaccine Revenue and Gross Margin (2020-2025)
7.8.4 Shanghai Institute Varicella Vaccine Product Portfolio
7.8.5 Shanghai Institute Recent Developments
8 North America
8.1 North America Varicella Vaccine Revenue (2020-2031)
8.2 North America Varicella Vaccine Revenue by Type (2020-2031)
8.2.1 North America Varicella Vaccine Revenue by Type (2020-2025)
8.2.2 North America Varicella Vaccine Revenue by Type (2026-2031)
8.3 North America Varicella Vaccine Revenue Share by Type (2020-2031)
8.4 North America Varicella Vaccine Revenue by Application (2020-2031)
8.4.1 North America Varicella Vaccine Revenue by Application (2020-2025)
8.4.2 North America Varicella Vaccine Revenue by Application (2026-2031)
8.5 North America Varicella Vaccine Revenue Share by Application (2020-2031)
8.6 North America Varicella Vaccine Revenue by Country
8.6.1 North America Varicella Vaccine Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Varicella Vaccine Revenue by Country (2020-2025)
8.6.3 North America Varicella Vaccine Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Varicella Vaccine Revenue (2020-2031)
9.2 Europe Varicella Vaccine Revenue by Type (2020-2031)
9.2.1 Europe Varicella Vaccine Revenue by Type (2020-2025)
9.2.2 Europe Varicella Vaccine Revenue by Type (2026-2031)
9.3 Europe Varicella Vaccine Revenue Share by Type (2020-2031)
9.4 Europe Varicella Vaccine Revenue by Application (2020-2031)
9.4.1 Europe Varicella Vaccine Revenue by Application (2020-2025)
9.4.2 Europe Varicella Vaccine Revenue by Application (2026-2031)
9.5 Europe Varicella Vaccine Revenue Share by Application (2020-2031)
9.6 Europe Varicella Vaccine Revenue by Country
9.6.1 Europe Varicella Vaccine Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Varicella Vaccine Revenue by Country (2020-2025)
9.6.3 Europe Varicella Vaccine Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China Varicella Vaccine Revenue (2020-2031)
10.2 China Varicella Vaccine Revenue by Type (2020-2031)
10.2.1 China Varicella Vaccine Revenue by Type (2020-2025)
10.2.2 China Varicella Vaccine Revenue by Type (2026-2031)
10.3 China Varicella Vaccine Revenue Share by Type (2020-2031)
10.4 China Varicella Vaccine Revenue by Application (2020-2031)
10.4.1 China Varicella Vaccine Revenue by Application (2020-2025)
10.4.2 China Varicella Vaccine Revenue by Application (2026-2031)
10.5 China Varicella Vaccine Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Varicella Vaccine Revenue (2020-2031)
11.2 Asia Varicella Vaccine Revenue by Type (2020-2031)
11.2.1 Asia Varicella Vaccine Revenue by Type (2020-2025)
11.2.2 Asia Varicella Vaccine Revenue by Type (2026-2031)
11.3 Asia Varicella Vaccine Revenue Share by Type (2020-2031)
11.4 Asia Varicella Vaccine Revenue by Application (2020-2031)
11.4.1 Asia Varicella Vaccine Revenue by Application (2020-2025)
11.4.2 Asia Varicella Vaccine Revenue by Application (2026-2031)
11.5 Asia Varicella Vaccine Revenue Share by Application (2020-2031)
11.6 Asia Varicella Vaccine Revenue by Country
11.6.1 Asia Varicella Vaccine Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Varicella Vaccine Revenue by Country (2020-2025)
11.6.3 Asia Varicella Vaccine Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Varicella Vaccine Revenue (2020-2031)
12.2 SAMEA Varicella Vaccine Revenue by Type (2020-2031)
12.2.1 SAMEA Varicella Vaccine Revenue by Type (2020-2025)
12.2.2 SAMEA Varicella Vaccine Revenue by Type (2026-2031)
12.3 SAMEA Varicella Vaccine Revenue Share by Type (2020-2031)
12.4 SAMEA Varicella Vaccine Revenue by Application (2020-2031)
12.4.1 SAMEA Varicella Vaccine Revenue by Application (2020-2025)
12.4.2 SAMEA Varicella Vaccine Revenue by Application (2026-2031)
12.5 SAMEA Varicella Vaccine Revenue Share by Application (2020-2031)
12.6 SAMEA Varicella Vaccine Revenue by Country
12.6.1 SAMEA Varicella Vaccine Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Varicella Vaccine Revenue by Country (2020-2025)
12.6.3 SAMEA Varicella Vaccine Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.